
Dr. Pravas Chandra Mishra is a senior Clinical Haematologist and Haemato-Oncology specialist serving as Professor of Haematology at Amrita Hospital, Faridabad. With more than 17 years of experience following his DM in Clinical Haematology, he specialises in blood disorders, haematological cancers and advanced stem cell transplantation.
He completed his MBBS and MD in Internal Medicine from Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, followed by a DM in Clinical Haematology from AIIMS, New Delhi. He subsequently joined the AIIMS faculty and held academic positions, including Professor of Haematology, until 2017.
His clinical expertise includes leukaemia, myeloma, bone marrow failure syndromes, haemoglobin disorders, coagulation disorders and other benign and malignant blood conditions. He also specialises in matched unrelated donor transplantation, haploidentical transplantation and advanced cellular therapies.
Dr. Mishra previously established the Blood and Marrow Transplant unit at Max Super Speciality Hospitals, Patparganj and Vaishali. His academic contributions include more than 100 publications in national and international journals, several international clinical fellowships and recognition through the Geeta Medal for research in oncology at AIIMS.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Pravas Chandra Mishra for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Pravas Chandra Mishra regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Pravas Chandra Mishra holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.